ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ES...
June 10 2019 - 7:00AM
Business Wire
Presentation highlights preliminary results
from phase 1/2 study of miransertib in patients with PIK3CA-related
Overgrowth Spectrum (PROS) and Proteus Syndrome (PS)
ArQule, Inc. (Nasdaq:ARQL), today announced it will present
preliminary results from the company’s phase 1/2 study of its
pan-AKT inhibitor, miransertib (ARQ 092), in patients with
PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS)
in an oral presentation at the European Society of Human Genetics
Conference held from June 15-18, 2019 in Gothenburg, Sweden.
Presentation Details:
Title:
An open-label, phase 1/2 study of
miransertib (ARQ 092), an oral pan-AKT inhibitor, in patients (pts)
with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus Syndrome
(PS): study design and preliminary results (NCT03094832)
Presentation #:
C17.6
Session:
C18 - Therapies
Date:
Monday, June 17, 2019
Time:
2:15-2:30 p.m. CEST
Location:
F1+F2+F3
About MiransertibMiransertib (ARQ 092) is an orally
available, selective, pan-AKT (protein kinase B) inhibitor that
potently inhibits AKT 1, 2 and 3 isoforms. Additionally, it binds
both the active and inactive forms of AKT which directly inhibits
and prevents membrane localization, respectively. Dysregulation of
AKT has been implicated in a variety of rare overgrowth diseases
and cancers; however, there are currently no approved inhibitors of
AKT. AKT inhibitors, either as single agent or combination therapy,
show significant promise in molecularly defined patient
populations. We are in process of initiating a registrational trial
in both Proteus syndrome and PIK3CA-Related Overgrowth Spectrum
(PROS). Miransertib has been granted Rare Pediatric Disease
Designation and Fast Track Designation by the U.S. Food and Drug
Administration (FDA), as well as Orphan Designation by the FDA and
European Medicines Agency in the rare overgrowth disease, Proteus
syndrome.
About ArQuleArQule is a biopharmaceutical company engaged
in the research and development of targeted therapeutics to treat
cancers and rare diseases. ArQule’s mission is to discover, develop
and commercialize novel small molecule drugs in areas of high unmet
need that will dramatically extend and improve the lives of our
patients. Our clinical-stage pipeline consists of four drug
candidates, all of which are in targeted, biomarker-defined patient
populations, making ArQule a leader among companies our size in
precision medicine. ArQule’s pipeline includes: ARQ 531, an orally
bioavailable, potent and reversible dual inhibitor of both wild
type and C481S-mutant BTK, in phase 1 for patients with B-cell
malignancies refractory to other therapeutic options; miransertib
(ARQ 092), a potent and selective inhibitor of the AKT
serine/threonine kinase, planned to initiate registrational trial
cohorts in Proteus syndrome and PROS in 2019, and in phase 1b in
combination with the hormonal therapy, anastrozole, in patients
with advanced endometrial cancer; ARQ 751, a next generation highly
potent and selective AKT inhibitor, in phase 1 for patients with
AKT1 and PI3K mutations; and derazantinib, a multi-kinase inhibitor
designed to preferentially inhibit the fibroblast growth factor
receptor (FGFR) family, in a registrational trial for iCCA in
collaboration with Basilea and Sinovant. ArQule’s current discovery
efforts are focused on the identification and development of novel
kinase inhibitors, leveraging the Company’s proprietary library of
compounds.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190610005186/en/
Corporate:Kathleen FarrenInvestor Relations &
Executive Assistant to the CFOir@arqule.com
Media:Cait Williamson, Ph.D.LifeSci Public Relations(646)
751-4366cait@lifescipublicrelations.com
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Aug 2024 to Sep 2024
ArQule (NASDAQ:ARQL)
Historical Stock Chart
From Sep 2023 to Sep 2024